Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Hepatitis

  Free Subscription


06.11.2023

1 Arch Virol
1 Dig Dis Sci
1 Gastroenterology
2 Hepatology
1 J Hepatol
1 J Infect Dis
2 J Med Virol
2 J Viral Hepat
1 MMWR Recomm Rep
1 Pediatrics
1 PLoS One
1 PLoS Pathog
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Arch Virol

  1. GAO H, Fan H, Xie H
    miR-HCC2 suppresses hepatitis B virus replication by inhibiting the activity of the enhancer I/X promoter.
    Arch Virol. 2023;168:282.
    PubMed         Abstract available


    Dig Dis Sci

  2. JINDAL A, Sharma MK, Vijayaraghavan R, Sm S, et al
    Severity of Acute Portal Hypertension Determines the Clinical Outcomes in Severe Alcoholic Hepatitis.
    Dig Dis Sci. 2023 Oct 31. doi: 10.1007/s10620-023-08144.
    PubMed         Abstract available


    Gastroenterology

  3. ZHENG D, Fang Z, Sun J
    Which is more clinically relevant: end-of-treatment or off-treatment predictors of hepatitis B relapse and surface antigen loss?
    Gastroenterology. 2023 Oct 25:S0016-5085(23)05196.
    PubMed        


    Hepatology

  4. JENG WJ, Chien RN, Liaw YF
    Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
    PubMed        

  5. DENG R, Wang Z, Liu Y, Sun J, et al
    Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
    PubMed        


    J Hepatol

  6. PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
    Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
    J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
    PubMed         Abstract available


    J Infect Dis

  7. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
    Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
    J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
    PubMed         Abstract available


    J Med Virol

  8. KRUMBHOLZ A, Marcic A, Valentin M, Schemmerer M, et al
    Hepatitis A outbreak in a refugee shelter in Kiel, northern Germany.
    J Med Virol. 2023;95:e29185.
    PubMed         Abstract available

  9. TANG L, Li Q, Chen L, Li X, et al
    IL-21 collaborates with anti-TIGIT to restore NK cell function in chronic HBV infection.
    J Med Virol. 2023;95:e29142.
    PubMed         Abstract available


    J Viral Hepat

  10. NATOUR RT, Midlej A, Mahajna E, Kopelman Y, et al
    Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life.
    J Viral Hepat. 2023 Nov 3. doi: 10.1111/jvh.13894.
    PubMed         Abstract available

  11. TRELOAR C, Rance J, Bryant J, Lafferty L, et al
    "There's too much power in this number. It's freaking the whole response out": the views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia.
    J Viral Hepat. 2023 Nov 2. doi: 10.1111/jvh.13896.
    PubMed         Abstract available


    MMWR Recomm Rep

  12. PANAGIOTAKOPOULOS L, Sandul AL, Conners EE, Foster MA, et al
    CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children - United States, 2023.
    MMWR Recomm Rep. 2023;72:1-21.
    PubMed         Abstract available


    Pediatrics

  13. SALEH E, Jhaveri R
    Earlier Screening of Infants With Perinatal Hepatitis C Exposure: A Key Step Towards Elimination.
    Pediatrics. 2023 Nov 1. doi: 10.1542/peds.2023-064242.
    PubMed         Abstract available


    PLoS One

  14. ANGELO L, Vaillant A, Blanchet M, Labonte P, et al
    Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen.
    PLoS One. 2023;18:e0293167.
    PubMed         Abstract available


    PLoS Pathog

  15. DRAVID P, Murthy S, Attia Z, Cassady C, et al
    Phenotype and fate of liver-resident CD8 T cells during acute and chronic hepacivirus infection.
    PLoS Pathog. 2023;19:e1011697.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  16. ZHOU J, Sukhova K, Peacock TP, McKay PF, et al
    Omicron breakthrough infections in vaccinated or previously infected hamsters.
    Proc Natl Acad Sci U S A. 2023;120:e2308655120.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.